Samsara BioCapital GP, LLC bought $1.3M of NGNE
owner at Neurogene Inc.. 48,770 shares at an average of $25.83, traded Nov 26, 2024, filed Nov 27, 2024.
Score components
- +12Role10% owner
- +25Trade size$1.3M at market
- 0Relative to holdingsHoldings up 2.9%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.0%, 3m -33.3%, 6m -31.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-027861, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 26, 2024 | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +20,748 | $24.91 | $517k | 1,689,105 | Nov 27, 2024 |
| Nov 26, 2024 | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +10,803 | $26.01 | $281k | 1,699,908 | Nov 27, 2024 |
| Nov 26, 2024 | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +15,219 | $26.73 | $407k | 1,715,127 | Nov 27, 2024 |
| Nov 26, 2024 | POpen-market purchase Common Stockindirect: By Samsara BioCapital, L.P. | +2,000 | $27.50 | $55k | 1,717,127 | Nov 27, 2024 |
Related signals
Other insiders at Neurogene Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 11Weak | Neurogene Inc. | Stuart Cobb Chief Scientific Officer | $141k 6,797 shares | -18% | |
| 10Weak | Neurogene Inc. | Stuart Cobb Chief Scientific Officer | $103k 6,797 shares | -25% | |
| 10Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $76k 4,501 shares | -6% | |
| 61Notable | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $491k 24,000 shares | +45% | |
| 65Notable | Neurogene Inc. | Rachel McMinn Chief Executive Officer | $969k 47,500 shares | +4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.